DANBURY, Conn., May 13 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq:
BIOD) today announced that the Company has been selected for inclusion in
the NASDAQ Biotechnology Index (NBI), effective as of the market's open on
Monday, May 19, 2008.
"We are pleased to be included in the NASDAQ Biotechnology Index and
believe Biodel's inclusion is a result of the Company's consistent
achievement of its goals," stated Dr. Solomon Steiner, Chairman and Chief
Executive Officer of Biodel. "We look forward to reporting on future 2008
goals including the results from our two pivotal Phase III clinical trials
for VIAject(TM) in September or October and the filing of our NDA
submission for a suite of VIAject(TM) presentations by the end of 2008."
Launched in 1993, the NBI includes biotechnology and pharmaceutical
companies listed on the NASDAQ National Market that meet minimum
requirements for market value, average daily share volume and seasoning as
a public company. The index is ranked on a semi-annual basis in May and
November and serves as the basis for the iShares Nasdaq Biotechnology Index
Fund (Amex: IBB). For more information about the Nasdaq Biotechnology
Index, including eligibility criteria, visit http://www.nasdaq.com.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the
development and commercialization of innovative treatments for endocrine
disorders, such as diabetes and osteoporosis. Biodel's product candidates
are developed by using VIAdel(TM) technology, which reformulates existing
FDA- approved peptide drugs. The Company's lead product candidate,
VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in
development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM)
is currently being tested in two pivotal Phase III clinical trials.
Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation
of insulin in the Phase I stage of clinical testing, and two pre-clinical
osteoporosis product candidates. For further information regarding Biodel,
please visit the Company's website at http://www.biodel.com.
BIOD-G
SOURCE Biodel Inc.
 back to top
Related links:
http://www.biodel.com
CONTACT:
Investors: Rebecca Der, rder@burnsmc.com,
Media, Carney Noensie, cnoensie@burnsmc.com, both of Burns
McClellan, Inc., +1-212-213-0006, for Biodel Inc.
|
